Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced top-line data demonstrating clinically meaningful treatment effects across multiple endpoints and a...
The media landscape is rapidly changing. With the continued rise of social media as a medium and information accessibility steadily increasing, the mainstream...
Silo's SPC-15 was developed in collaboration with Columbia University The post Silo Pharma to test a novel experimental intranasal formulation for PTSD...
The same day California lawmakers signed off on a bill to legalize psychedelics last week, staffers at the state’s Legislative Analyst’s Office (LAO)...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
Awakn Life Sciences has submitted a Clinical Trial Application for a phase III trial for its lead program for the treatment of Severe Alcohol Use Disorder....
Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly. In fact, I’ve uncovered seven of the top...
AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder...
Harm reduction and integration for people choosing to use psychedelics is important for both safety and maximization of benefits. Simply put, psychedelic...